XencorXNCR
XNCR
About: Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Employees: 280
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
16% more capital invested
Capital invested by funds: $1.25B [Q2] → $1.45B (+$200M) [Q3]
5% more funds holding
Funds holding: 199 [Q2] → 209 (+10) [Q3]
3.96% less ownership
Funds ownership: 106.94% [Q2] → 102.98% (-3.96%) [Q3]
28% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 81
61% less call options, than puts
Call options by funds: $64K | Put options by funds: $163K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
49%
upside
Avg. target
$32
71%
upside
High target
$37
96%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo 40% 1-year accuracy 2 / 5 met price target | 96%upside $37 | Overweight Initiated | 12 Dec 2024 |
Piper Sandler Edward Tenthoff 24% 1-year accuracy 11 / 45 met price target | 59%upside $30 | Overweight Upgraded | 2 Dec 2024 |
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 81%upside $34 | Outperform Reiterated | 8 Nov 2024 |
JP Morgan Brian Cheng 28% 1-year accuracy 5 / 18 met price target | 49%upside $28 | Overweight Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 4 articles about XNCR published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Negative
Zacks Investment Research
1 week ago
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
Zacks Investment Research
2 weeks ago
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
2 weeks ago
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
2 months ago
Xencor to Participate at Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Location: New York City 7th Annual Evercore HealthCONx Conference Date: Wedn.
Positive
Seeking Alpha
2 months ago
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of the phase 1b/2a study, using Plamotamab for the treatment of patients with multi-drug resistant Rheumatoid Arthritis, expected 1st half of 2025. XmAb657 is a long-acting CD19 X CD3 bispecific antibody being developed to target patients with autoimmune disorders; Phase 1 trial initiation for this program expected 2nd half of 2025.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
2 months ago
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Charts implemented using Lightweight Charts™